These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31228281)

  • 1. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data.
    Pane M; Coratti G; Sansone VA; Messina S; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Brigati G; Tacchetti P; Salmin F; de Sanctis R; Lucibello S; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Ann Neurol; 2019 Sep; 86(3):443-451. PubMed ID: 31228281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I SMA "new natural history": long-term data in nusinersen-treated patients.
    Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Brigati G; Tacchetti P; Salmin F; De Sanctis R; Lucibello S; Pera MC; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Ann Clin Transl Neurol; 2021 Mar; 8(3):548-557. PubMed ID: 33547876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.
    Aragon-Gawinska K; Seferian AM; Daron A; Gargaun E; Vuillerot C; Cances C; Ropars J; Chouchane M; Cuppen I; Hughes I; Illingworth M; Marini-Bettolo C; Rambaud J; Taytard J; Annoussamy M; Scoto M; Gidaro T; Servais L
    Neurology; 2018 Oct; 91(14):e1312-e1318. PubMed ID: 30158155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function.
    Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; Brolatti N; Mizzoni I; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Salmin F; De Sanctis R; Pera MC; Piastra M; Genovese O; Ricci F; Cavallina I; Masson R; Zanin R; Agosto C; Salomon E; Bruno I; Magnolato A; Bertini E; Tiziano FD; Bovis F; Mercuri E;
    Eur J Neurol; 2023 Jun; 30(6):1755-1763. PubMed ID: 36880698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function.
    Pane M; Palermo C; Messina S; Sansone VA; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Brigati G; de Sanctis R; Coratti G; Lucibello S; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Neuromuscul Disord; 2018 Jul; 28(7):582-585. PubMed ID: 29960818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.
    Aragon-Gawinska K; Daron A; Ulinici A; Vanden Brande L; Seferian A; Gidaro T; Scoto M; Deconinck N; Servais L;
    Dev Med Child Neurol; 2020 Mar; 62(3):310-314. PubMed ID: 31799720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One Year of Newborn Screening for SMA - Results of a German Pilot Project.
    Vill K; Kölbel H; Schwartz O; Blaschek A; Olgemöller B; Harms E; Burggraf S; Röschinger W; Durner J; Gläser D; Nennstiel U; Wirth B; Schara U; Jensen B; Becker M; Hohenfellner K; Müller-Felber W
    J Neuromuscul Dis; 2019; 6(4):503-515. PubMed ID: 31594245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
    Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
    N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
    Shin HJ; Na JH; Lee H; Lee YM
    Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
    Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L;
    N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
    Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Bishop KM; Foster R; Liu Y; Ramirez-Schrempp D; Schneider E; Bennett CF; Wong J; Farwell W
    Lancet Child Adolesc Health; 2021 Jul; 5(7):491-500. PubMed ID: 34089650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy.
    De Sanctis R; Pane M; Coratti G; Palermo C; Leone D; Pera MC; Abiusi E; Fiori S; Forcina N; Fanelli L; Lucibello S; Mazzone ES; Tiziano FD; Mercuri E
    Neuromuscul Disord; 2018 Jan; 28(1):24-28. PubMed ID: 29174525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).
    Glanzman AM; McDermott MP; Montes J; Martens WB; Flickinger J; Riley S; Quigley J; Dunaway S; O'Hagen J; Deng L; Chung WK; Tawil R; Darras BT; Yang M; Sproule D; De Vivo DC; Kaufmann P; Finkel RS; ;
    Pediatr Phys Ther; 2011; 23(4):322-6. PubMed ID: 22090068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.